Clinical Trial Search

Primary: Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite Score — 31.96; 0.96 score

Primary: Number of Participants Without Respiratory Reaction During Aspirin Desensitization — 0; 5 Participants — p=0.036

Primary: Number of Patients With Adverse Events as a Measure of Safety Per Treatment Group in Period I — 0; 0; 1; 1 participants

Primary: Progression-Free Survival (PFS) at Any Site — 10.7; 10.2 Months — p=0.551

Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Baricitinib Following a Single Oral Dose — 49.8; 49.6; 47.8; 47.9 nanograms per milliliter (ng/mL)

Primary: Ilivia Family Related SADE-free Rate Through 3 Months — 91; 12 Participants — p=0.0004

Primary: Number of Participants With Adverse Events in All Subjects — 11 Participants

Primary: Number of Subjects With Drug Related Adverse Events — 0.0; 33.3; 16.7; 16.7 Percentage of participants

Primary: Change in Postural Control - Reaction Time on the Limits of Stability Test (Smart Equitest Balance Master System) — 0.09; -0.02 Seconds

Primary: Effectiveness of PINPOINT and IC2000 in the Identification of Lymph Nodes Defined as the Proportion of Confirmed Lymph Nodes Identified — 232; 239 Confirmed Lymph Nodes

Primary: Percentage of Subjects With Drug Related Adverse Events — 22.2; 22.2; 11.1; 66.7 Percentage of participants

Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound S-Warfarin — 3.50; 3.73 nanogram per milliliter (ng/mL)

Primary: Safety as Assessed by Number of Participants With Any Adverse Events (AE)s — 4; 4 Participants — p=0.8958

Primary: Quality of Parent-teen Communication (General- All Groups) — 77.8; 73.0; 77.2; 69.1 units on a scale — p=.906

Primary: Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine — 0.9; 8.4; 13.3; 16.9 percent change — p=< 0.0001